Overview

* CVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectations

* U.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awareness

* Gross margin rises to 87% in Q3 2025 due to higher selling prices, efficiencies

Outlook

* CVRx ( CVRX ) expects full-year 2025 revenue between $55.6 mln and $56.6 mln

* Company forecasts Q4 2025 revenue between $15.0 mln and $16.0 mln

* CVRx ( CVRX ) raises full-year 2025 gross margin guidance to 85%-86%

Result Drivers

* U.S. GROWTH - Expansion into new sales territories and increased Barostim awareness drove 10% revenue growth in the U.S.

* IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 250, supporting higher implant volumes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $14.69 $14.20

Revenue mln mln (7

Analysts

)

Q3 EPS -$0.49

Q3 Net -$12.87

Income mln

Q3 Gross 87.00%

Margin

Q3 Basic -$0.49

EPS

Q3 Gross $12.75

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for CVRx Inc ( CVRX ) is $12.00, about 16.8% above its November 4 closing price of $9.99

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)